Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Endlessly Scouting for lithium that is not being mined from the ground for sale:
“5:00a ET 7/25/2022 - Globe Newswire
Jourdan Starts Soil Sampling Program at Preissac-La Corne and Baillarge Projects
EQNX::TICKER_START (TSX-V:JOR),(OTC US:JORFF),(Other OTC:JORFF),(Boerse Stuttgart - Freiverkehr:2JR1), EQNX::TICKER_END JOURDAN RESOURCES INC. (TSXV: JOR; OTCQB: JORF, FRA:2JR1) ("Jourdan" or the "Company") is pleased to announce that it has commenced a soil sampling program on the majority of its claims located in the long-established lithium mining district of Preissac-La Corne, which is approximately 35km north of Val-d'Or in Quebec, Canada.
The sampling program is being conducted on a 400m x 200m regional grid and represents a pre-cursor to a potential future drilling program. A field crew consisting of geological and exploration technicians has been mobilized to the area and has begun collecting soil samples. Soil samples are being collected using two-person teams equipped with picks and shovels. Samples are being collected from the b-horizon at a depth ranging from 10 cm to 90 cm. Approximately 1,000 sites are scheduled to be sampled. To date, the soil sampling technique, utilizing both in-situ and pXRF analysis directly in the field, is working very efficiently to test these large areas rigorously, rapidly and cost-effectively. Samples are being analyzed on a daily and weekly basis for rubidium (Rb) and tantalum (Ta) by the latest model X-505 portable XRF gun from SciAps. Samples are then sent to Impact Global Solutions (IGS) lab in Delson, Quebec for pathfinder element analysis.
The soil sampling program is aimed at finding new lithium anomalies and showings in areas of known lithium mineralization at Baillarge, Preissac-La Corne, Duval Lithium in La Motte, as well as Vallee Lithium. We also expect to commence a geological mapping and prospecting program in the near future to run parallel with the soil sampling program.
Sample data collected includes UTM location, depth of sample, color, moisture content, texture (sand, silt, clay), and percentage, angularity and lithology of pebbles and or cobbles. Samples collected amount to approximately 1 kilogram of material and are placed in plastic sample bags. Wet samples are additionally placed into 5 ml plastic Ziploc bags to prevent contamination. At the end of the day, all samples are placed inside the Company's shop facility on a rack and allowed to dry for at least one week before shipping to Impact Global Solutions (IGS) lab in Delson, Quebec.
The geochemical soil sampling program was designed and is being sampled by GeoTasks Inc. technicial team from Sudbury, Ontario. Their technical team is supervised by OGQ compliant senior geologists.
"We are not only committed to the establishing an initial mineral resource at Vallee, our flagship property, but we are focussed on the further exploration at our Baillarge and Preissac-LaCorne properties," said Dr. Andreas Rompel, Jourdan's executive Chairman.
Jourdan's Chief Executive Officer, Rene Bharti, stated, "Jourdan is pleased to begin exploration on its other significant properties. The Company is keenly focused on establishing an initial mineral resource estimate at Vallee in the near term and commencing a drill program in the near future at its other two properties, Baillarge and Preissac-La Corne. With such a relatively large land package, Jourdan is fortunate to have other extremely interesting properties to explore and develop. We anticipate announcing our initial resource estimate on our Vallee property in the near term, but will continue to move towards an aggressive exploratory drill campaign on our Preissac-La Corne and Baillarge properties."
Figure 1: Soil sampling location on the Jourdan properties which are approximately 35km north of Val-d'Or.
https://www.globenewswire.com/NewsRoom/AttachmentNg/553c3a80-9b09-4511-bffd-8941be15d523
The Company's now completed diamond drilling program of 3,629m was intended to follow up on the results of a 40-tonne bulk sample collected in 2018, the fence line drilled in 2011, and follow-up drilling in 2021 along the western side of the Company's Vallee property, which borders the North American Lithium mine. As anticipated, the drilling program substantially extended the known deposit at the Company's Vallee property eastwards. Since February 2022, 18 holes of approximately 200m depth have been drilled, each aimed at the pegmatite swarm identified by the trenching of the bulk sample collected on the Vallee property in 2018. The assay results from the bulk sample revealed high Li2O grades (for more information, please see the Company's press release dated April 29, 2021, which is available under the Company's SEDAR profile at www.sedar.com), which have encouraged the Company to continue exploration and exploratory drilling along the strike and depth extents of its Vallee property.
Jourdan has significantly enlarged its database by adding more drillholes since the start of the exploration work in 2011. The 2011 drilling comprised 21 drillholes (4,256m), the 2021 campaign consisted of eight drillholes (1,680m) and with the completed 3,629m in 2022, Jourdan has more than 9,490m (47 holes) of core that the Company intends to use in the future to establish an initial mineral resource estimate.
”
More shares offered:
“6:00p ET 7/21/2022 - Globe Newswire
Jourdan Upsizes Private Placement Financing
EQNX::TICKER_START (TSX-V:JOR),(OTC US:JORFF),(Other OTC:JORFF),(Boerse Stuttgart - Freiverkehr:2JR1), EQNX::TICKER_END NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
JOURDAN RESOURCES INC. (TSXV: JOR; OTCQB: JORF, FRA:2JR1) ("Jourdan" or the "Company") is pleased to announce that as a result of increased investor demand the Company is increasing its previously announced private placement financing (the "Initial Offering") of common shares issued on a flow-through basis (the "Flow-Through Shares") from up to 10,000,000 Flow-Through Shares to up to 14,000,000 Flow-Through Shares at a price of $0.10 per Flow-Through Share, for aggregate gross proceeds from the issuance of both units and Flow-Through Shares of up to $2.4 million (the "Upsized Offering"). For more information about the Initial Offering and details of the units to be issued thereunder, please see the Company's press release dated June 29, 2022, which is available under the Company's SEDAR profile at www.sedar.com.
Closing of the Upsized Offering is expected to occur by the end of July 2022. All securities issued in connection with the Upsized Offering will be subject to a statutory hold period of four-months and one day. Completion of the Upsized Offering is subject to a number of conditions, including without limitation, receipt of TSX Venture Exchange ("TSXV") approval. Finder's fees may be paid to eligible finders in accordance with the policies of the TSXV consisting of a cash commission equal to up to 9% of the gross proceeds raised under the Upsized Offering and finder warrants ("Finder Warrants") in an amount equal to up to 9% of the number of Units and Flow-Through Shares sold pursuant to the Upsized Offering. Each Finder Warrant will entitle the holder thereof to purchase one common share of the Company at a price of $0.10 per share for a period of 24 months following the closing date of the Upsized Offering. The Company intends to use the net proceeds from the issuance of the Units and the Flow-Through Shares for working capital and general corporate purposes and to fund exploration expenditures on its Vallee, Preissac-La Corne, and Baillarge lithium mining properties.”
No mining completed.
Could see a price increase based on one month consolidation ending tomorrow
20 days ago:
“Joseph Onyero, Chief Executive Officer of Bebuzee, Inc., said: "We have completed the re-structuring of the Company and are taking steps to be fully audited, fully reporting, file a Form 10 and a RegA. This will give shareholders more information and make the Company more transparent."
He concluded: "We will also be addressing the final components of our "Super App" in the coming weeks, which is scheduled to be launched in a couple of months."“
3 weeks is tomorrow, if he is taking steps to file forms maybe file a form per week to stay on schedule set in the PR.
He’d make way more money via added revenues with the market attention of a booming SP in this time frame:
Senators Discuss Marijuana Reform At Historic Hearing Following Legalization Bill IntroductionPublished 5 hours ago on July 26, 2022
https://www.marijuanamoment.net/watch-live-senators-discuss-marijuana-reform-at-historic-hearing-following-legalization-bill-introduction/
Reinvesting his salary now, all in, would be looking out for his own financial interests because he’d have more shares and a repaired relationship with shareholders going into a new phase of legalization
1.5 mill at .0068 is 10,200 dollars.
“ Tauriga Sciences Inc. Chief Executive Officer Completes 1,500,000 Share Insider Purchase
May 09 2022 - 03:31PM
InvestorsHub NewsWire
Share On Facebook
New York, NY -- May 9, 2022 -- InvestorsHub NewsWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences and Pharmaceutical Development Company, today announced that its Chief Executive Officer, Seth M. Shaw, completed an insider purchase for 1,500,000 shares of Tauriga Sciences Inc. common stock (quoted on the OTCQB - symbol: “TAUG”). This Insider Purchase was completed between the dates of May 5-9, 2022 and a corresponding Form 4 will be filed this week.
E-Commerce Website: www.taurigum.com
”
If there is an insider purchase every three months then that is August 9th, given the Congressional schedule:
“ Tentative 2022 Legislative Schedule ; Aug 8 - Sep 5, State Work Period,”
I think he will time the reinvestment correctly and coincide with Congress passing a bill by August recess so they have something to speak to their constituents about when they go back to their States.
Senators Discuss Marijuana Reform At Historic Hearing Following Legalization Bill IntroductionPublished 5 hours ago on July 26, 2022
https://www.marijuanamoment.net/watch-live-senators-discuss-marijuana-reform-at-historic-hearing-following-legalization-bill-introduction/
MS = Microsoft connection to the adventure? Is the private backer of the business Bill Gates himself?
The company sells product on the e-commerce website, online sales in the overall industry would increase if federal legalization occurs because so many people are afraid to buy anything related to CBD etc across state lines even if it is legal to do so. The rumor is that Congress is debating the bill and that is why volume is in the sector, higher volume means higher SP, if the CEO has share and money now would be the time to hold the shares and reinvest his money in the company to gain attention prior to the bill being passed, draw attention to the product in advance when consumers are interested in what they could get.
Yield sign, can this even bought using most brokers?
2 billion o/s needs a r/s
Share Structure
Market Cap Market Cap
1,173,524
07/25/2022
Authorized Shares
3,420,000,000
07/22/2022
Outstanding Shares
2,347,048,846
07/22/2022
Restricted
455,499,690
07/22/2022
Unrestricted
1,891,549,156
07/22/2022
Held at DTC
0
07/22/2022
Float
990,225,342
10/22/2013
Par Value
0.001
“Senate Confirms Key VA Official Who Expanded New Jersey’s Medical Marijuana Program And Backs Federal Legalization”
https://www.marijuanamoment.net/senate-confirms-key-va-official-who-expanded-new-jerseys-medical-marijuana-program-and-backs-federal-legalization/
“A federal handbook published by the National Institute of Standards and Technology is getting a new cannabis-focused section with recommendations on potency measurement, packaging, labeling and other issues. It’s the result of a vote at a recent National Conference of Weights and Measures event.
Senate Majority Leader Chuck Schumer’s (D-NY) marijuana legalization bill got two additional cosponsors, but one of them—Sen. Patty Murray (D-WA)—emphasized in her press release about signing on that Congress should still enact cannabis banking legislation as soon as possible.
The Drug Enforcement Administration is being sued again for refusing to allow terminally ill cancer patients to access psilocybin-assisted therapy despite Right to Try laws.
Michigan regulators announced $20 million in marijuana revenue-funded grants to support research on the benefits of medical cannabis for military veterans.
/ FEDERAL
President Joe Biden released a “Safer America Plan” that includes a proposal to eliminate the sentencing disparity between crack and powder cocaine but also pushes to “impose tougher penalties for fentanyl trafficking.”
Former President Donald Trump again suggested that people who sell drugs should receive the death penalty.
Senate Majority Leader Chuck Schumer (D-NY) tweeted, “It’s time to end the federal prohibition of cannabis.”
Sens. Ron Wyden (D-OR) and John Cornyn (R-TX) led a group of 29 other senators in filing a resolution calling on Russia to free American basketball player Brittney Griner, who is being detained for possessing cannabis vapes.
Sen. Rand Paul (R-KY) tweeted, “Unfortunately federal bureaucracy continues to block Schedule I drugs under Right to Try. I’m proud to lead this bipartisan legislation with @SenBooker.”
House Financial Services Committee Chair Maxine waters (D-CA) touted the inclusion of marijuana banking provisions in the National Defense Authorization Act.
Rep. Ed Perlmutter (D-CO) tweeted about Senate Majority Leader Chuck Schumer’s (D-NY) new marijuana legalization bill, saying. “Thank you for your work on this bill and broader cannabis reforms. Look forward to working together to make sure we can enact commonsense cannabis reform this year!”
Rep. Barbara Lee (D-CA) tweeted, “.@SenBooker@SenSchumer @RonWyden took a huge step toward cannabis justice today with #CAOA. Removing cannabis from the list of controlled substances is overdue. It’s time the federal govt caught up with the states, end the war on drugs, & reinvest in communities most impacted. We look forward to working together to finally pass a comprehensive cannabis bill into law.”
Rep. Earl Blumenauer (D-OR) sent a press release praising Senate leadership’s filing a marijuana legalization bill.
The House bill to remove barriers to marijuana research got four new cosponsors for a total of ten.
/ STATES
Illinois Gov. J.B. Pritzker (D) cheered regulators’ issuing 149 new marijuana dispensary licenses to social equity applicants, tweeting, “Illinois is leading the way in addressing the War on Drugs as no state has before, and dispensary ownership that reflects our state’s diversity is a product of that commitment… These licenses represent a significant step toward accountability for the decades of injustice preceding cannabis legalization and we will continue to prioritize equity in this process.”
Kentucky Gov. Andy Beshear (D) tweeted, “Ninety percent of Kentucky adults support medical cannabis and the Team KY Medical Cannabis Advisory Committee will help ensure every voice is heard as I weigh executive action that could provide access for those suffering from chronic pain or our veterans suffering from PTSD.”
Florida Democratic gubernatorial candidate Charlie Crist, currently a congressman, said he wants to legalize marijuana and use the revenue to support teachers and law enforcement.
Hawaii Republican gubernatorial candidate BJ Penn said he supports legalizing marijuana.
Iowa’s attorney general is pushing to legalize fentanyl test strips.
A Minnesota representative authored an op-ed on a new law legalizing THC-infused edibles and drinks.
Montana regulators proposed rules on additional canopy license tiers for marijuana cultivators and authorizing dispensary customer loyalty programs.
Louisiana regulators filed rules on raw medical cannabis products.
Colorado regulators issued an informational notification about corydalis as an ingredient in marijuana products.
Washington State regulators published a policy statement on the transfer of wet cannabis flower from producers to processors.
California regulators said they expect to seize more than $1 billion worth of illegal cannabis products.
Connecticut regulators discussed the future of the medical cannabis program at a meeting.
New York regulators are hosting workshops to help equity businesses prepare to apply for marijuana dispensary licenses.
”
https://www.marijuanamoment.net/new-cannabis-section-in-federal-standards-handbook-newsletter-july-25-2022/
TAUR’s e-commerce presence and trust in its products puts the company in a unique and positive position in this legalization time frame.
“FORBES DIGITAL ASSETS
Ethereum Cofounder Reveals ‘Surge’ Expectations After Radical Upgrade As Ether Price Leaves Bitcoin, BNB, XRP, Solana, Cardano And Dogecoin In The Dust
Billy Bambrough
Senior Contributor
Jul 22, 2022,06:45am EDT
Ethereum, the second-largest cryptocurrency after bitcoin, has seen its price surge higher in recent weeks as excitement builds ahead of a long-waited, radical upgrade.
The ethereum price is up almost 50% over the last month, topping $1,600 per ether, and leaving the bitcoin price and other top ten cryptocurrencies BNBBNB -2.8%, XRPXRP -4.1%, solana, cardano and dogecoin in the dust even as research shows markets could be close to "full capitulation."
Now, ethereum cofounder and the project's spiritual leader Vitalik Buterin has revealed his plans for ethereum following the "merge" upgrade—with the "surge" next in a series of improvements designed to make the network more secure and decentralized.
"At the end of this road map, ethereum will be a much more scalable system," Buterin said in comments reported by Fortune, speaking at the Ethereum Community Conference in France and outlining a plan that includes the surge, verge, purge and splurge upgrades. "By the end, ethereum will be able to process 100,000 transactions per second."
The surge upgrade is expected to increase scalability for "shadow chain" rollups—a way to scale ethereum by making transactions cheaper—through sharding; dividing transactions across several different chains in a way that's designed to decrease fees and speed up transactions.
The following verge upgrade will try to optimize ethereum storage and reduce node size, while the purge will involve removing some network history.
"The purge: trying to actually cut down the amount of space you have to have on your hard drive, trying to simplify the ethereum protocol over time and not requiring nodes to store history," Buterin said in comments reported by Decrypt, adding the splurge upgrade will be "all of the other fun stuff."
According to Buterin, ethereum development is currently just 40% complete, compared to bitcoin's 80%. After ethereum's merge upgrade, penciled in for September, Buterin thinks ethereum will still only be around 55% complete.“
Only 55%.
Scale the mountain
“On July 20, 2021 Twin Vee PowerCats Co., TVPC's subsidiary, became a publicly-traded company on NASDAQ and now trades under the ticker symbol VEEE.
TVPC, the parent company, remains the largest shareholder of Twin Vee PowerCats Co. owning 4,000,000 shares of common stock of Twin Vee PowerCats Co. on the TVPC balance sheet.
As of today, TVPC has nominal business operations and TVPC's main asset remains the 4,000,000 VEEE shares.
TVPC is subject to a one-year lock-up agreement following the date of the VEEE IPO last month.
TVPC intends to distribute the VEEE shares to the shareholders of TVPC once the lock-up has expired. ”
Update request on the above
Fonu is at .0001 still, pink current did nothing except redirect investment from good companies to a bad share structure, similar to here, a r/s is needed:
JAMN:
Share Structure
Market Cap Market Cap
1,735,890
07/22/2022
Authorized Shares
19,999,999,990
06/30/2022
Outstanding Shares
11,572,599,423
06/30/2022
Restricted
1,991,324,193
06/30/2022
Unrestricted
9,581,275,230
06/30/2022
Held at DTC
9,575,325,940
06/30/2022
Float
96,912,313
05/31/2016
Par Value
0.001
RS soon 1:2 to 1:30
“8:05a ET 7/25/2022 - PR Newswire
CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022
Company reiterates support of proposals for the authorization to increase number of shares available for issuance by the Company and authorization for the Board to effect a reverse stock split at their discretion
Video to shareholders from John Climaco, CEO of CNS Pharmaceuticals now available on the Company's website
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today urged shareholders to vote in favor of the proposals outlined in the Company's Definitive Proxy Statement (the "Proxy") for the upcoming Annual Shareholder Meeting to be held Wednesday, July 27, 2022.
https://mma.prnewswire.com/media/1120277/CNS_Pharmaceuticals_Logo.jpg
The proposals outlined in the Proxy include the authorization to increase the number of shares available for issuance by the Company and the authorization for the Board of Directors to effect a reverse stock split of the outstanding shares of the Company's common stock, at a split ratio of between 1-for-2 and 1-for-30 at their discretion.
"While we remain whole-heartedly dedicated to the advancement of our potentially pivotal global trial of Berubicin, we must also focus on our continued strategic fiduciary obligations to all stakeholders. After careful thought and consideration by both the management team and the board of directors, we strongly believe having these tools available at our discretion will enable us to effectively finance the Company and thereby drive the ongoing clinical development forward. To be clear, if approved, these tools will only be used if needed. It is necessary, however, as a cash-burning, development-stage company, to have the ability to issue stock on the market to raise capital and to have the best market for our shareholders to use when they wish to trade our stock. I, along with the rest of the CNS Pharmaceuticals team, urge shareholders to thoughtfully consider this opportunity to further equip the board of directors with available tools that, if needed, can be used to both maintain our NASDAQ listing by satisfying the minimum bid price requirement and enhance the long-term growth prospects of the Company by broadening our financing alternatives," commented John Climaco, CEO of CNS Pharmaceuticals. "In this turbulent and unpredictable market, we are dedicated to addressing the existential financial threats to the Company that currently exist. These tools will put the Company in the best position to manage challenging market conditions and to act, as always, in the best interest of all shareholders."
Shareholders are urged to carefully review the Proxy and accompanying materials as they contain important information regarding the Share Consolidation and its consequences to shareholders. A copy of the Proxy is available in the Investors section of the Company's website and on the U.S. Securities and Exchange Commission's website at www.sec.gov.
YOUR VOTE IS IMPORTANT. VOTE TODAY!
A proxy form or voting instruction form accompanied the Meeting materials you received by mail. Instructions on how to vote, which vary depending on whether you are a registered or beneficial shareholder of the Company, are provided in the Circular and the proxy form or voting instruction form.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.
”
Back to .34 gap
One month consolidation complete, can and should go much higher based on incoming revenue from Europe, and potential projects via historic demand for energy solutions
Going lower now mid .50s
1.30 gap fill first
Going way lower, at least to 1.33
Fill the gap at 2.75
Psychedelics should be taken seriously, Musk stated.
“Entheon Biomedical begins enrollment in phase 1 study of DMT for addiction disorders
March 15 2022 - 11:00AM
Seeking Alpha”
Check back in September for this ticker when 6 month consolidation ends
They could not pay their debenture conversions and even if they did they would still have 13 million to pay that didn’t request conversion, their increase in authorized shares to pay for the conversions is legalized theft from shareholders, if the vote is no the company will have no way to pay their debentures and will default on those obligations, requiring bankruptcy: “The foregoing resulted in the Company's inability to process approximately $1,400,000 of pending conversions, which conversions will be honored at a later date once the Company has increased its authorized shares.“
The owners of this company want to declare bankruptcy and ride off into the sunset to enjoy their wealth stashed away, the effort to preserve the economics of the business is a fake effort and pretend concern for shareholders, they seek to blame shareholders for the no vote which is why that is promoted here because a no vote is their legal excuse for failure to avoid paying their stashed wealth to shareholders in a future lawsuit, they overlooked their financial obligations and a shareholder lawsuit re: fiduciary duty is obvious and they are trying to delay and avoid that payout. All imo
That’s what they said on the 20th, how can investors have confidence in any of these drugs after the failure in the short term, the next report isn’t until later in ‘22, the rumor of that report is diminished in the near term imo, thus lower
Need RS 10:1, 15:1, 20:1, too many shares exist currently, vote yes
Share Structure
Market Cap Market Cap
13,451,586
07/22/2022
Authorized Shares
499,560,659
07/22/2022
Outstanding Shares
494,543,611
07/22/2022
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
413,126,632
07/22/2022
Float
493,000,053
05/12/2022
Par Value
0.00001
Next week close at .0162, then news in the next 24 hrs, then higher imo.
VTGN .15 buy?
This was posted as stock analysis on 7/20/22 (follow the prose):
““2 “Strong Buy” Penny Stocks That Could Go Boom
Michael Marcus (Author)
Between the Fed’s aggressive policy tightening to rein in inflation and deteriorating economic data, volatility has become a seemingly ever-present facet of the stock market. While the current economic landscape has spurred fear among investors, others view market volatility as a unique buying opportunity.
Opportunity is the key word – and sometimes the hardest thing for investors to see. To find names that can deliver solid returns and now come with a bargain price tag, investors will often turn to penny stocks, or those trading for less than $5 per share.
Sure, there could be a very good reason these tickers are so affordable, but should there be even minor share price appreciation, massive percentage gains could materialize, along with hefty profits for investors.
So, how are investors supposed to determine which names have what it takes to make a comeback? Follow the pros.
Using TipRanks’ database, we were able to pinpoint two promising penny stocks, according to Wall Street analysts. Both tickers boast a Strong Buy consensus rating and could climb over 300% higher in the year ahead.
VistaGen Therapeutics (VTGN)
We’ll start with VistaGen, a biopharmaceutical research company with a focus on disorders of the central nervous system. The company’s leading programs are new treatments for anxiety and depression, serious conditions with large potential patient bases. According to recent governmental health authority data, some 264 million people worldwide suffer from depression-related disorders, 19.4 million US adults have experienced at least one major depressive episode, and some 25 million people suffer from social anxiety disorders (SADs) in the US alone. This is the population that VistaGen aims to help.
The company has three main drug candidate programs, each one with a different pharmacological mode of action and target condition. The leading candidate is PH94B, a new treatment for social anxiety disorder. The drug, administered by nasal spray, is currently undergoing the PALISADE clinical trials. PALISADE-1, a phase 3 study that followed 208 patients across 15 clinical sites in the US, is focused on the use of PH94B as an acute treatment for rapid onset anxiety in adults. VistaGen announced last month that the study is now complete, and topline results will be available this year. PALISADE-2, another phase 3 trial of identical size and scope, in still underway, with topline results expected in late 2022. PH94B has been granted ‘fast track’ status by the FDA.
The other two clinical programs, PH10 and AV-101, are less advanced. PH10 is under development as a treatment for depression, and is also administered as a nasal spray. An exploratory phase 2a trial showed promise, and VistaGen is assembling an Investigational New Drug application for the FDA, to gain approval for a phase 2b clinical trial of PH10 in the treatment of major depressive disorder.
AV-101, a drug candidate being studies as a treatment for neurological disorders, is the subject of a phase 1b drug-drug interaction study, in combination with probenecid. AV-101 is an orally dosed product, and VistaGen is considering further trials as a combination therapy with probenecid.
Currently going for only $0.82 apiece, at least one member of the Street believes that now is the right time to snap up shares.
Baird’s Brian Skorney has reviewed VistaGen’s current position and sees plenty to be optimistic about. The key point, in his view, is the soon-to-be-released data from PALISADE-1, which should give investors reason to buy in.
“We continue to view the inbound top-line readout, expected no later than mid-August, as a crucial catalyst for the PH94B opportunity in SAD. We continue to think the existing data support the expectation that the study will hit on its primary endpoint, offering a favorable risk/reward at the current valuation,” Skorney opined.
“We continue to see substantial upside potential with PH94B in SAD and other forms of anxiety disorders, and believe current valuation of VTGN underestimates the clinical proof of concept and the commercial potential,” the analyst added.
To this end, Skorney rates VTGN an Outperform (i.e. Buy), and his price target, at $9, suggests just how much he expects that outperformance: up to 997% in the coming year. (To watch Skorney’s track record, click here)
Other analysts are on the same page. With 2 additional Buy ratings, the word on the Street is that VTGN is a Strong Buy. On top of this, the average price target is $7, suggesting robust growth of ~754%. (See VTGN stock forecast on TipRanks)”
https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-could-go-boom-3?utm_source=advfn.com&utm_medium=referral
Tip Ranks Last….-85%.
Never posted on RGBP and I follow zero accounts
Growth potential very high when demand is high
Only 19.6 OS, Cup and handle could see massive increase on volume soon, banks and major firms that believe in Web3 and the Metaverse will want DatChat to succeed greatly if only just as a primary building block of the entire long term project
It didn’t move off the .15 the entire day so maybe it will go lower, need something other than the current story to get willing buyers at higher prices, time could be a good thing because it gives them time to fix the drugs so they actually work, could see .01 without consistent company communication (weekly at minimum) midterm/long term, investors will be constantly asking “prove that you didn’t give up completely”
The transaction date of this 10% insider purchase says 7/30/22 at .74:
https://ih.advfn.com/stock-market/NASDAQ/vistagen-therapeutics-VTGN/stock-news/88605870/statement-of-changes-in-beneficial-ownership-4
Here we go on the adventure
Change the name to Beijing Group Corp
.0162 close for news
Company can’t meet timelines it sets for itself and then offers no explanation for the delay
“ said Dr. Gourdoupi. "From my start at the Company more than fifteen years ago as a Senior Scientist to now as I join its board of directors, I have always known that Advent's best in class technology and world class team will power the green energy revolution. With the Green HiPo project approved and ratified, the widespread adoption of fuel cells as a truly viable fossil fuel alternative is closer than ever.”
The share price increases are currently antagonizing and that can make for a huge spike if that negative energy turns positive for some reason
Some stocks have been trading counter to normal expectations recently on seemingly innocuous or even bad news, a lot of money is moving around the globe due to Russia/Ukraine and parked in what could be classified as ‘interesting gambles’ on zero current positive news and some meager communication like a “notice of late filing”, weed as a current topic of the day helps that same gamble money flow into weed stocks in the near term imo, tough to explain why it is happening but I think it has to do with money fleeing Russia or China investing erratically to deliberately frustrate U.S. day traders who thrive on charts and normalcy, this stock could see a surge because the Chinese Army values that chaos and disruption of the confusion that would cause US markets.
As if 3/31 the company already made back the initial investment and riding on free shares, no way to know till the filing if the unrealized gain was realized prior to the VTGN drop:
“At March 31, 2021
Beginning of Period Cost $ 277,500
Sales Proceeds $ 302,827
Unrealized Gain(Loss)$ 837,300 “
Closing prices
March 31 1.26
July 21 1.07
So assuming the same number of shares the value of the investment was probably somewhere in the $600,000 area and if not sold in time would be worth about $70,000 today, the price of VTGN dropped in 2019 in similar fashion and rallied 10x over the next two years, .33 to 3.30 in 2021.